Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Clears Off-The-Shelf Stem Cell Therapy for Buerger's

Executive Summary

Stempeutics Research has been granted limited approval to make and sell the first allogeneic cell therapy product for Buerger’s Disease in India. The stem cell therapy, which was granted orphan drug designation by the EMA last year, may hold potential in certain additional indications as well.

You may also be interested in...



PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence on the Asian marketplace.

Video Interview: Placental Stem Therapy Offers 'Off The Shelf' Promise

Pluristem Therapeutics chair and CEO Zami Aberman explains to Mike Ward, global director of content for Informa Pharma Insights how stem cell therapy will shape the industry. Using placental cells and a proprietary, three-dimensional (3D) technology platform, Pluristem is developing "off the shelf" cell therapies for a broad spectrum of diseases. Pluristem converts human placental stem cells into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. The company's pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. Aberman tells Mike Ward that his company intends to use the $17m it raised in 2015 to complete current clinical studies and start new ones.

Stempeutics weighs Japan tie-up for stem cell therapy

Japan continues to attract interest in the area of regenerative medicine. Indian firm Stempeutics Research now says it is eyeing collaboration opportunities for its stem-cell based drug, Stempeucel, initially targeted for the treatment of critical limb ischemia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel